-- Findings underscore potential of XENLETA as a first-in-class pleuromutilin antibiotic for the IV and oral treatment of CABP in adults, including older patients with comorbidities who are at risk of poor outcomes -- -- Pooled analysis of data by age group from pivotal LEAP 1 and LEAP 2 Phase 3
-NTAP designation highlights need for novel antibiotics to fight drug-resistant infections and advance antimicrobial stewardship -CONTEPO first Qualified Infectious Disease Product to receive NTAP conditional approval prior to FDA approval DUBLIN, Ireland , Sept.
DUBLIN, Ireland , Aug. 31, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that management will participate in two upcoming
DUBLIN, Ireland , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its second quarter financial
DUBLIN, Ireland , July 30, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder , Chief Executive Offer at
- XENLETA represents the first new antibiotic class approved for patients with CAP in Europe in nearly 20 years -XENLETA approval provides urgently needed short-course, empiric monotherapy treatment option for CAP aligned with core principles of antimicrobial stewardship DUBLIN , July 28, 2020
-In pre-clinical model, lefamulin shows anti-inflammatory activity comparable to dexamethasone -Nabriva awarded grant funding from the Austrian Research Promotion Agency to further characterize the anti-inflammatory and immunomodulatory properties of Lefamulin DUBLIN, Ireland , July 23, 2020 (GLOBE
-XENLETA to be marketed exclusively in Canada by Sunovion Pharmaceuticals Canada Inc. DUBLIN, Ireland , July 16, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to
Accretive transaction creates synergies and scale that strengthen Nabriva’s community-focused commercialization organization to optimize product uptake Nabriva partners with Amplity Health to provide community-focused customer engagement and sales initiatives for SIVEXTRO and XENLETA ®
